Research and Markets: Primary Immune Deficiency (PID) - Pipeline Review, H2 2012

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/s368nb/primary_immune_def) has announced the addition of Global Markets Direct's new report "Primary Immune Deficiency (PID) - Pipeline Review, H2 2012" to their offering.

“Primary Immune Deficiency (PID) - Pipeline Review, H2 2012”

Global Markets Direct's, 'Primary Immune Deficiency (PID) - Pipeline Review, H2 2012', provides an overview of the Primary Immune Deficiency (PID) therapeutic pipeline. This report provides information on the therapeutic development for Primary Immune Deficiency (PID), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Immune Deficiency (PID). 'Primary Immune Deficiency (PID) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Primary Immune Deficiency (PID).

- A review of the Primary Immune Deficiency (PID) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Primary Immune Deficiency (PID) pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Primary Immune Deficiency (PID).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) pipeline depth and focus of Primary Immune Deficiency (PID) therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/s368nb/primary_immune_def

Source: Global Markets Direct